- Home
- CANF vs CJET Comparison
CANF vs CJET Comparison
Compare CANF & CJET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- CJET
- Stock Information
- Founded
- CANF 1994
- CJET 2009
- Country
- CANF Israel
- CJET China
- Employees
- CANF N/A
- CJET N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- CJET Auto Manufacturing
- Sector
- CANF Health Care
- CJET Consumer Discretionary
- Exchange
- CANF Nasdaq
- CJET Nasdaq
- Market Cap
- CANF 7.9M
- CJET 8.3M
- IPO Year
- CANF N/A
- CJET N/A
- Fundamental
- Price
- CANF $1.18
- CJET $1.95
- Analyst Decision
- CANF Strong Buy
- CJET
- Analyst Count
- CANF 2
- CJET 0
- Target Price
- CANF $14.00
- CJET N/A
- AVG Volume (30 Days)
- CANF 408.4K
- CJET 184.9K
- Earning Date
- CANF 05-06-2025
- CJET 04-29-2025
- Dividend Yield
- CANF N/A
- CJET N/A
- EPS Growth
- CANF N/A
- CJET N/A
- EPS
- CANF N/A
- CJET N/A
- Revenue
- CANF $674,000.00
- CJET $10,275,000.00
- Revenue This Year
- CANF $461.72
- CJET N/A
- Revenue Next Year
- CANF N/A
- CJET N/A
- P/E Ratio
- CANF N/A
- CJET N/A
- Revenue Growth
- CANF N/A
- CJET 31.31
- 52 Week Low
- CANF $1.22
- CJET $1.09
- 52 Week High
- CANF $4.69
- CJET $23.94
- Technical
- Relative Strength Index (RSI)
- CANF 37.60
- CJET 51.23
- Support Level
- CANF $1.14
- CJET $1.68
- Resistance Level
- CANF $1.27
- CJET $2.00
- Average True Range (ATR)
- CANF 0.12
- CJET 0.22
- MACD
- CANF -0.02
- CJET -0.01
- Stochastic Oscillator
- CANF 6.03
- CJET 48.83
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About CJET Chijet Motor Company Inc.
Chijet Motor Co Inc is engaged in the research and development, production and sales of new energy vehicles. New energy vehicles refer to plug-in electric vehicles including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans.